Multi Variant Covid-19 Vaccine: Trial of world's first multi-variant corona vaccine begins, trial in the UK

Posted on 21st Sep 2021 by rohit kumar

Multi Variant Covid-19 Vaccine, the delta variant of the coronavirus has become a cause of concern for the whole world at this time. It is being claimed in studies that the risk of this deadly variant of corona may be reduced in people taking the vaccine. However, research is going on about which vaccine is more effective on the delta variant. Meanwhile, the trial of the world's first multi-variant corona vaccine against different variants of the coronavirus has started in Britain. The trial of the world's first multi-variant corona vaccine against Covid-19 has started in Manchester, UK.

 

On Monday, a 60-year-old married couple became the first participants to appear in the trial, Xinhua news agency reported. The world's first multi-variant corona vaccine is being trialed in collaboration between the University of Manchester and the National Health Service (NHS) Foundation Trust. The drug, called GRT-R910, launched by US pharmaceutical company Gritstone, claims to boost the immune response of the first-generation COVID-19 vaccine to the broader forms of SARS-Cov-2, which causes the disease.

 

Moderna vaccine more effective in protecting against delta variant

 

The US Centers for Disease Control and Prevention (CDC) said in a recent study that Moderna's vaccine may be more effective than Pfizer and Johnson & Johnson vaccines in protecting against delta variants. In the study, published in the journal Morbidity and Mortality Weekly Reports, researchers say that although all corona vaccines can protect against the risk of hospitalization or death due to infection. However, America's modern vaccine is more effective in protecting against the delta variant. According to the study, the modern vaccine can reduce the risk of hospitalization by up to 95 percent. At the same time, Pfizer's vaccine is 80 percent effective while Johnson & Johnson's is 60 percent effective.

 

AstraZeneca not recognized by Covishield, controversy over Britain's new Covid-19 travel rules

 

Britain has made changes to its Covid-19 travel rules but has also given rise to a new controversy. Britain is being accused of discriminating against India. There is also increasing pressure on the UK government to review the rules set for passengers coming from India. This is because under the new rules Britain will not consider those taking the 'Covishield' vaccine to be vaccinated, while those who have received the Oxford AstraZeneca vaccine have been recognized. A lot of statements are coming out in the country in Britain regarding this discrimination.

Other news